Dr. Reddy's Laboratories’ Post

𝐏𝐡𝐚𝐫𝐦𝐚 𝐢𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐩𝐢𝐧𝐤 𝐨𝐟 𝐡𝐞𝐚𝐥𝐭𝐡 The Indian #pharma_sector is flexing its muscles. In the last 12 months, the #NSE Pharma has returned 50%, comfortably beating the Nifty that went up by 31%, while also returning an average 19% over the last three years, compared with Nifty’s 15%. This is a sharp reversal from the sector’s underperformance in four out of the previous five years. Blocks which were built and added over the decade are finally falling into place for the sector. It is focused on two markets – a $24-bn branded generics domestic bazaar and a $28-bn formulations and API exports. The domestic market is dominated by Indian companies with the top-10 holding a 44% share. Rising non-communicable diseases due to lifestyle changes and increasing income levels that improve affordability and competitive pricing – average price hike is 5-7% – should ensure that a 8-10% annual growth rate will continue for the foreseeable future. Pharma companies have added sales force, expanded doctor reach, ventured into trade generics and collaborated with multinational corporations.  India’s $28-bn exports grew 10% last year and 8% in the last six years. India has the highest number of FDA-compliant plants outside the US, nearly 1,400 WHO-GMP and 253 European Directorate of Quality Medicines-approved plants with modern state-of-the-art technology. It is not for nothing that India is called the pharmacy of the world. With the healthcare burden in developed countries straining systems and cramping access, India presents a perfect partner of choice for those seeking quality medicine and intervention at affordable rates. Indian companies have steadily added capacity as well as capability – rolling out a stream of complex and biological products. India’s pharma prowess is buttressed by its abundance of skilled manpower, low labour costs, friendly government policies – SEZ, #pharma parks, PLI – uninterrupted electricity and commitment to global ESG best practices. 𝐒𝐨𝐮𝐫𝐜𝐞:- https://lnkd.in/g2k36XVw #latestnews #latestarticle #trendingnews #trend #topnews #todaysnews

🚀Embracing Change in India's Pharma Industry: Transforming Through Emerging Channels 🌟 Imagine working in an Industry where the End Consumer is not the decision-maker! In India's pharmaceutical sector, the end consumer/buyer isn't the decision-maker. With restrictions on direct marketing to consumers, the focus has traditionally been on engaging with healthcare professionals. However, the digital era and events like COVID-19 have spurred a shift in patient behavior towards preventive care and improved therapy outcomes. As India's healthcare landscape evolves, emerging channels like e-pharmacies, organized retail chains, and B2B digital platforms are becoming indispensable. They're not just trends; they're vital components of a dynamic ecosystem. During my tenure at Cipla, I've witnessed firsthand how these channels aren't merely avenues to push products. They're powerful tools for addressing real-world challenges, such as therapy education, disease awareness, and stakeholder engagement. Innovation isn't always about reinventing the wheel. As Tom Freston aptly said, "Innovation is taking two things that exist and putting them together in a new way." Let's drive change together and shape the future of healthcare in India! 💡 #PharmaIndustry #HealthcareInnovation #DigitalTransformation #Cipla #Innovation #EPharmacies #EmergingChannel

INDIAN ECONOMY UPDATE The "#MakeinIndia" initiative is pivotal in reducing reliance on imported #ActivePharmaceuticalIngredients (#APIs) by enhancing domestic manufacturing. This effort bolsters self-reliance and ensures that critical healthcare supplies are readily available, as Union Minister of State (Independent Charge) for Science and Technology Dr. #JitendraSingh highlighted at the 6th CII Pharma & Life Sciences Summit 2024. He noted that India ranks 3rd in pharmaceutical production by volume and 14th by value, with a significant shift toward developing biopharmaceuticals and biosimilars. He emphasized the need for India to lead the next industrial revolution in the biotech sector under Prime Minister Mr. #NarendraModi's vision. He also mentioned that every third tablet consumed globally is produced in India, with a spurious drug incidence of just 0.0245%, according to a #CDSCO survey. Improving the infrastructure for transporting #pharmaceuticals across diverse climatic regions is essential to maintain efficacy. With India producing 65% of the world's vaccines, the country significantly impacts health outcomes, especially for low- and middle-income nations. India’s bioeconomy has grown 13-fold in the last decade, supported by nearly 6,000 bio-startups. Continued investment in R&D and fostering a strong startup ecosystem are crucial, alongside the Anusandhan National Research Foundation (#ANRF), which has a budget of US$ 5.96 billion (Rs. 50,000 crore) over 5 years to enhance industry-academia collaborations in key sectors like advanced materials, electric vehicle (#EV) mobility, and health technology.

📢 Case Study :MANKIND PHARMA LTD : From Rural Roots to Pharmaceutical Powerhouse Mankind Pharma's rise to success is a fascinating story of strategic targeting, affordability, and capitalizing on underserved markets. Here's a breakdown of their key strategies: 1. Rural Focus: Unlike competitors chasing urban markets, Mankind Pharma turned its attention to rural India. This vast, underserved population had limited access to affordable healthcare. Mankind recognized the opportunity and built its presence there. 👩👩👧👧 2. Price Penetration: Understanding the rural population's economic constraints, Mankind adopted a value-based pricing strategy. Their medicines were priced competitively, making them accessible to a wider audience. 💱 3. Powerful Field Force: Mankind invested heavily in a strong field marketing team. These representatives, numbering over 2,800, directly interacted with doctors and pharmacies in rural areas, promoting Mankind's products and educating healthcare providers. 🎇 4. Product Portfolio: Mankind focused on a diverse range of therapeutic areas, offering over 1,000 products. This comprehensive approach catered to various healthcare needs in the targeted market. 🥇 5. Brand Building: Mankind created strong brand identities for its products. A prime example is "Manforce, " a leading anti-impotency drug, that became a household name in India. 🚦 6. Operational Efficiency: Mankind implemented robust systems like SAP S/4HANA to improve data analysis and optimize inventory management. This focus on efficiency helped control costs and maintain affordability . 🚒 The Result: 🛤 Through this strategic approach, Mankind Pharma achieved remarkable success:- Growth Leader: Mankind became one of India's fastest-growing pharmaceutical companies. Market Share: Several of their brands secured top positions in their respective categories. Global Expansion: Mankind's success extended beyond India. They have a presence in over 34 international markets. Affordability Champion: Mankind remained committed to making quality healthcare accessible to all. Conclusion : ✒ Mankind Pharma's story serves as an inspiration for businesses looking to succeed in emerging markets. It highlights the importance of understanding customer needs, adopting innovative strategies, and focusing on operational excellence. #MankindPharma #PharmaSuccess #BusinessStrategy #CustomerCentric #BrandBuilding #IndianPharma #Healthcare #Entrepreneur #casestudy #success #pharmaceuticalndustry

#FOM | Sharing his views on Celebrating 10 Years of Make In India, Sanjaya Mariwala, Executive Chairman & MD, OmniActive Health Technologies and President Association of Herbal and Nutraceutical Manufacturers of India (AHNMI) noted, "Government initiatives like the Production Linked Incentive (PLI) and Make in India have triggered a boost in manufacturing. This shows in the manufacturing sector’s contribution to India’s GDP, which is 17 per cent, and is expected to reach 25% by 2025. To maintain this momentum, India must extend the PLI to more sectors, focus on Research and Development and build a robust supply chain. This will facilitate a smooth transition to the adoption of the China Plus One strategy and consolidate India’s position globally.”   We are thrilled to introduce this industry expert as our Brand ambassador for The Festival of Manufacturing.   Join us on March 7, 2024, at Dr. Ambedkar International Centre, Delhi for his insights on 'Celebrating 10 Years of Make In India.' Register for our delegate registrations and plant celebrations now! Plant registrations: https://lnkd.in/dy55fsMD Delegate registrations: https://lnkd.in/dgvz6c3H Mobil India 🇮🇳 Ace Micromatic Group Limited igus India Kandui Industries Private Limited #fom #manufacturing #manufacturingexcellence #manufacturinginnovation #manufacturingindustry #makeinindia

India emerged as a major player in the Asia-Pacific region, contributing to almost 30% of the region's share of global healthcare deal activity in 2023. India hosted 22 deals in 2023 with a total value of $4.6 billion. In the previous year, i.e. 2022, the deal value was $4.7 billion.   👉 Three forces behind India’s rise 1️⃣ Spending on private and public healthcare:  ✔ The fast-growing middle class is spending more on healthcare. Government health expenditures have risen significantly over the past decade (29% in 2014–15 to 39% in 2021–22) and are expected to grow further. ✔ India’s powerful pharma manufacturing hub status has also contributed.   2️⃣ Booming pharma manufacturing and services:  ✔ India’s rise to a top-3 global manufacturer of pharmaceuticals by volume and the top global generics manufacturer is propelled because of -Supportive government policy (including the Production Linkage Incentive program) -A vast pool of chemistry and engineering talent -Strengthening the pharma ecosystem ✔ Covid further boosted India to the top position in vaccine manufacturing, supplying 50% of global vaccine demand. 3️⃣ Evolving healthcare technology ecosystem:  ✔ A young population eager to engage digitally remains strong for Indian companies operating at the intersection of healthcare and technology, especially in fitness and wellness. ➡ I believe India will be a giant in the healthcare industry in future, do you? Source: Bain & Company DKMS BMST Foundation India DKMS Life Science Lab DKMS Deutschland DKMS Group DKMS UK DKMS US LinkedIn LinkedIn for CEOs #india #asiapacific #healthcare #leader

Despite being one of the world’s fastest-growing economies and a hub for healthcare innovation, India remains an underexplored market for many global pharmaceutical companies. But why? The reluctance often stems from legacy mindsets, risk aversion, and an over-reliance on mature markets. While these established markets are crucial, the future of healthcare growth lies in expanding horizons—and India is a goldmine of untapped potential. India boasts: A population of 1.4 billion with growing healthcare needs A booming digital health ecosystem A government increasingly focused on healthcare reform and innovation. Emerging Middle class Yet, many pharma companies are hesitant to dive in. The challenges are real, but so are the rewards. If we as an industry continue to overlook opportunities in high-potential markets like India, we risk stagnating, while more agile players move forward. The future isn’t just about competing in the US or Europe; it’s about believing in the untapped potential of emerging markets. It's time to stop viewing India as "too complex" and start seeing it for what it truly is: the next frontier for growth. #PharmaGrowth #IndiaOpportunity #NewMarkets #HealthcareInnovation #BelieveInGrowth

The India pharma sector in India is poised for a massive transformation, with growth predicted to reach a staggering $55 billion by 2030! India is taking the lead globally in the evolving field of healthcare, changing both lives and the economy. We at Pharmarack are not only seeing this trend, we are spearheading it. We guarantee smooth supply chains and more intelligent business choices by putting retailers and distributors in real-time communication. Come along with us as we take the lead on this amazing journey to a healthy future! Read full article here: https://lnkd.in/dwUES7SB #Pharmarack #PharmaTrends #PharmAnalytics #IndianPharmaSector #HealthcareTransformation #HealthTech #PharmaGrowth #Healthcare #PharmInsights #PharmaTrends #PharmaMarket #PharmaIndustry

🚀 Unlocking Value Chain Synchronization in India’s Pharma Industry: A Journey Toward Excellence 🚀 Value chain synchronization is the heartbeat of any thriving industry, and the Indian pharmaceutical sector is no exception. Let’s explore how this strategic alignment can propel India’s pharma industry toward unprecedented heights! 🌐 Understanding Value Chain Synchronization: 🌿 Definition: Value chain synchronization involves harmonizing processes across the entire pharmaceutical ecosystem, from research labs to patient care. 🌟 Benefits: Cost Efficiency: Streamlined processes reduce waste and enhance financial performance. Responsiveness: Swift adaptation to market shifts and regulatory changes. Quality Assurance: Coordinated efforts lead to superior product quality. Competitive Edge: Agility in a dynamic landscape. The Current State: 📊 Maturity Level: On the EFESO Value Chain Maturity Scale, India’s pharma value chain currently stands at Level 3 (Managed): Defined processes with room for standardization. Metrics in place but optimization potential remains. 🌱 Progress: We’ve come far, but the journey continues. India @ 100 Vision: 🎯 Ambition: By 2030, India’s pharma industry aims to reach US$130 billion. By 2047, an audacious US$450 billion awaits. 🌠 Guiding Star: Our vision is clear—healthier lives, innovative breakthroughs, and global leadership. Roadmap to Maturity: 🌐 Digital Transformation: Embrace tech for real-time insights and predictive analytics. 🤝 Collaboration: Forge stronger bonds across the value chain. 🧪 Innovation: Invest in R&D, biotech, and novel therapies. 📜 Regulatory Excellence: Comply with global standards. 🌟 Talent Nurturing: Develop skilled professionals. Role: 🚀 Be the Catalyst: As leaders, influencers, and change-makers, let’s propel India’s pharma value chain to Level 5 (Synchronized). 🌏 Impact: Better healthcare, economic growth, and a legacy we’re proud of. Join hands, ignite innovation, and let’s script a success story that echoes through generations! 🙌🏽🔥 Connect with EFESO: Are you ready to be part of this transformative journey? Connect with us at EFESO to learn how we can help you optimize your value chain and achieve excellence in the pharma industry. Let’s make a difference together! 💪🔥 #PharmaExcellence #ValueChainSynchronization #IndiaAt100 #pharma #SupplyChain

#FOM | Sharing his views on Celebrating 10 Years of Make In India, Sanjaya Mariwala, Executive Chairman & MD, OmniActive Health Technologies and President Association of Herbal and Nutraceutical Manufacturers of India (AHNMI) noted, "Government initiatives like the Production Linked Incentive (PLI) and Make in India have triggered a boost in manufacturing. This shows in the manufacturing sector’s contribution to India’s GDP, which is 17 per cent, and is expected to reach 25% by 2025. To maintain this momentum, India must extend the PLI to more sectors, focus on Research and Development and build a robust supply chain. This will facilitate a smooth transition to the adoption of the China Plus One strategy and consolidate India’s position globally.”   We are thrilled to introduce this industry expert as our Brand ambassador for The Festival of Manufacturing.   Join us on March 7, 2024, at Dr. Ambedkar International Centre, Delhi for his insights on 'Celebrating 10 Years of Make In India.' Register for our delegate registrations and plant celebrations now! Plant registrations: https://lnkd.in/dy55fsMD Delegate registrations: https://lnkd.in/dgvz6c3H Mobil India 🇮🇳 Ace Micromatic Group Limited igus India Kandui Industries Private Limited #fom #manufacturing #manufacturingexcellence #manufacturinginnovation #manufacturingindustry #makeinindia